Drug patents …
… from Kazakhstan to Kalamazoo
Manage your formulary budget
Find generic entry opportunities
Proactively manage your pharmacy inventory
Anticipate generic drug launch
Deep knowledge on
small-molecule drugs and
the 110,000 global patents
|Title:||Biologically active B-chain homodimers|
|Abstract:||Dimeric proteins having substantially the same biological activity as PDGF are disclosed. More specifically, the protein may have two substantially identical polypeptide chains, each of the chains being substantially homologous to the B-chain of PDGF. Alternatively, the protein may have two polypeptide chains that are substantially identical to the B-chain of PDGF. In addition, proteins comprising polypeptides that are variants or derivatives of the B-chain of PDGF are also disclosed. Therapeutic compositions containing these proteins and methods for enhancing the wound-healing process in warm-blooded animals are also disclosed.|
|Inventor(s):||Murray; Mark J. (Seattle, WA), Kelly; James D. (Seattle, WA)|
|Assignee:||ZymoGenetics, Inc. (Seattle, WA)|
Patent Claim Types:|
see list of patent claims
|Compound; Composition; Use;|
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.